DIGESTIVE REDS Trademark

Trademark Overview


On Tuesday, February 7, 2023, a trademark application was filed for DIGESTIVE REDS with the United States Patent and Trademark Office. The USPTO has given the DIGESTIVE REDS trademark a serial number of 97784098. The federal status of this trademark filing is ABANDONED - INCOMPLETE RESPONSE as of Sunday, August 18, 2024. This trademark is owned by Biohm Health Inc.. The DIGESTIVE REDS trademark is filed in the Pharmaceutical Products category with the following description:

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liqu...
digestive reds

General Information


Serial Number97784098
Word MarkDIGESTIVE REDS
Filing DateTuesday, February 7, 2023
Status600 - ABANDONED - INCOMPLETE RESPONSE
Status DateSunday, August 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesProbiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; dietary supplements for medical use, namely, metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; fungal extracts sold as a component ingredient of nutritional supplements and vitamins and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's disease, ulcerative colitis and irritable bowel syndrome
NOT AVAILABLE"REDS"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 26, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBiohm Health Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCleveland, OH 44113

Trademark Events


Event DateEvent Description
Saturday, November 4, 2023ASSIGNED TO EXAMINER
Saturday, November 25, 2023NON-FINAL ACTION E-MAILED
Wednesday, April 26, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 25, 2023NON-FINAL ACTION WRITTEN
Saturday, November 25, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 26, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, May 5, 2024FINAL REFUSAL E-MAILED
Sunday, May 5, 2024FINAL REFUSAL WRITTEN
Sunday, May 5, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, August 5, 2024ABANDONMENT - INCOMPLETE RESPONSE
Monday, August 5, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, August 5, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 5, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, August 18, 2024ABANDONMENT NOTICE E-MAILED - INCOMPLETE RESPONSE